Rate of cardiovascular, renal and bone disease and their major risks factors in HIV-infected individuals on antiretroviral therapy in Spain

Knobel, Hernando; Domingo, Peré; Suárez-Lozano, Ignacio; Gutiérrez, Félix; Estrada, Vicente; Palacios, Rosario; Antela, Antonio; Blanco, José-Ramón; Fulladosa, Xavier; Refollo, Elena

doi:10.1016/j.eimce.2018.09.005

Cited by 5 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A significant proportion of CKD was observed in patients with obesity in this study, obesity has been mentioned as a risk factor for the development of CKD in several studies [ 41 , 42 ]. A compensatory hyperfiltration takes place in obese people to meet the higher metabolic needs of their increased body weight, chronically increased intraglomerular pressure can harm the kidneys and increase the likelihood of CKD development [ 43 ].…”

Section: Discussionsupporting

confidence: 53%

Prevalence of and factors associated with chronic kidney disease among patients infected with human immunodeficiency virus attending care and treatment centers at tertiary hospitals in dodoma, Tanzania

Mwise,

Magoma,

Meremo

2024

Heliyon

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 53%

Prevalence of and factors associated with chronic kidney disease among patients infected with human immunodeficiency virus attending care and treatment centers at tertiary hospitals in dodoma, Tanzania

Mwise,

Magoma,

Meremo

2024

Heliyon

View full text Add to dashboard Cite

“…Well-established risk factors for NAFLD include waist circumference, high triglycerides, diabetes [71] and high BMI [67,72]. Moreover, it is well-known that cardiovascular risk factors are highly prevalent in PLHIV [73]. Of particular concern is the clustering of some of these factors forming metabolic syndrome [74,75], the single most predictive factor of NAFLD.…”

Section: Discussionmentioning

confidence: 99%

Uncovering the NAFLD burden in people living with HIV from high‐ and middle‐income nations: a meta‐analysis with a data gap from Subsaharan Africa

et al. 2023

View full text Add to dashboard Cite

Introduction Non‐alcoholic fatty liver disease (NAFLD) has become a significant concern among people living with HIV (PLHIV), albeit its burden remains unclear. The primary objective of this systematic review (SR) and meta‐analysis (MA) was to estimate the prevalence of NAFLD and significant fibrosis in PLHIV. The secondary objective was to determine the risk factors for NAFLD among PLHIV. Methods We searched MEDLINE and Scopus from inception to 30 December 2022 for peer‐reviewed studies that included PLHIV and reported the prevalence of NAFLD. MA of proportions was used to estimate the pooled prevalence of NAFLD and significant fibrosis. MA of pre‐calculated effect estimates examined risk factors for NAFLD in PLHIV. Results We included 24 articles published between 2009 and 2022, encompassing 6326 PLHIV. The pooled prevalence of NAFLD was 38% (95% CI: 31–45%) with high heterogeneity (I2 = 96.3%). The pooled prevalence of significant fibrosis was 13% (95% CI: 8–18%) with high heterogeneity (I2 = 92.09%). Subgroup analyses showed a NAFLD prevalence of 40% (95% CI: 24–57%) in the United States, 33% (95% CI: 31–36) in Asia, 42% (95% CI: 24–61%) in Europe and 33% (95% CI: 29–37) in South America. When stratifying by income level, NAFLD was 39% (95% CI: 31–48) prevalent in PLHIV from high‐income economies and 34% in both upper‐middle‐income (95% CI: 31–37%) and lower‐middle‐income economies (95% CI: 28–41%). Higher body mass index (BMI) (OR = 1.32, 95% CI: 1.13–1.55; I2 = 89.9%), increasing triglycerides (OR = 1.48, 95% CI: 1.22–2.79; I2 = 27.2%) and dyslipidaemia (OR = 1.89, 95% CI: 1.32–2.71; I2 = 15.5%) were all associated with higher risk‐adjusted odds of NAFLD in PLHIV. Discussion The burden of NAFLD and significant fibrosis in PLHIV is significant. Therefore, targeted efforts to screen and diagnose NAFLD in this population are needed. Health services for PLHIV could include ways to target NAFLD risk factors, screen for liver disease and implement interventions to treat those with significant fibrosis or more advanced stages of liver disease. Taking no action to address NAFLD in PLHIV should not be an option. Conclusions This SR and MA found a 38% NAFLD and 13% significant fibrosis prevalence in PLHIV. Increasing triglyceride levels, higher BMI values and dyslipidaemia were associated with higher risk‐adjusted odds of NAFLD among PLHIV.

show abstract

HIV and Dyslipidemia

Malvestutto

Aberg

2020

Contemporary Cardiology

View full text Add to dashboard Cite

Rate of cardiovascular, renal and bone disease and their major risks factors in HIV-infected individuals on antiretroviral therapy in Spain

Cited by 5 publications

References 23 publications

Prevalence of and factors associated with chronic kidney disease among patients infected with human immunodeficiency virus attending care and treatment centers at tertiary hospitals in dodoma, Tanzania

Prevalence of and factors associated with chronic kidney disease among patients infected with human immunodeficiency virus attending care and treatment centers at tertiary hospitals in dodoma, Tanzania

Uncovering the NAFLD burden in people living with HIV from high‐ and middle‐income nations: a meta‐analysis with a data gap from Subsaharan Africa

HIV and Dyslipidemia

Contact Info

Product

Resources

About